464 related articles for article (PubMed ID: 23264317)
1. Assessment of the abuse of tapentadol immediate release: the first 24 months.
Dart RC; Cicero TJ; Surratt HL; Rosenblum A; Bartelson BB; Adams EH
J Opioid Manag; 2012; 8(6):395-402. PubMed ID: 23264317
[TBL] [Abstract][Full Text] [Related]
2. Nonmedical use of tapentadol immediate release by college students.
Dart RC; Bartelson BB; Adams EH
Clin J Pain; 2014 Aug; 30(8):685-92. PubMed ID: 24042351
[TBL] [Abstract][Full Text] [Related]
3. Assessment of Tapentadol API Abuse Liability With the Researched Abuse, Diversion and Addiction-Related Surveillance System.
Vosburg SK; Severtson SG; Dart RC; Cicero TJ; Kurtz SP; Parrino MW; Green JL
J Pain; 2018 Apr; 19(4):439-453. PubMed ID: 29224919
[TBL] [Abstract][Full Text] [Related]
4. Trends in abuse of Oxycontin and other opioid analgesics in the United States: 2002-2004.
Cicero TJ; Inciardi JA; Muñoz A
J Pain; 2005 Oct; 6(10):662-72. PubMed ID: 16202959
[TBL] [Abstract][Full Text] [Related]
5. The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS).
Cicero TJ; Dart RC; Inciardi JA; Woody GE; Schnoll S; Muñoz A
Pain Med; 2007 Mar; 8(2):157-70. PubMed ID: 17305687
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the risks of opioid abuse or dependence between tapentadol and oxycodone: results from a cohort study.
Cepeda MS; Fife D; Ma Q; Ryan PB
J Pain; 2013 Oct; 14(10):1227-41. PubMed ID: 23850177
[TBL] [Abstract][Full Text] [Related]
7. Trends in opioid analgesic abuse and mortality in the United States.
Dart RC; Surratt HL; Cicero TJ; Parrino MW; Severtson SG; Bucher-Bartelson B; Green JL
N Engl J Med; 2015 Jan; 372(3):241-8. PubMed ID: 25587948
[TBL] [Abstract][Full Text] [Related]
8. Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010.
Severtson SG; Bartelson BB; Davis JM; Muñoz A; Schneider MF; Chilcoat H; Coplan PM; Surratt H; Dart RC
J Pain; 2013 Oct; 14(10):1122-30. PubMed ID: 23816949
[TBL] [Abstract][Full Text] [Related]
9. Diversion and Illicit Sale of Extended Release Tapentadol in the United States.
Dart RC; Surratt HL; Le Lait MC; Stivers Y; Bebarta VS; Freifeld CC; Brownstein JS; Burke JJ; Kurtz SP; Dasgupta N
Pain Med; 2016 Aug; 17(8):1490-6. PubMed ID: 26814267
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain.
Daniels S; Casson E; Stegmann JU; Oh C; Okamoto A; Rauschkolb C; Upmalis D
Curr Med Res Opin; 2009 Jun; 25(6):1551-61. PubMed ID: 19445652
[TBL] [Abstract][Full Text] [Related]
11. Abuse-Deterrent Formulations and the Prescription Opioid Abuse Epidemic in the United States: Lessons Learned From OxyContin.
Cicero TJ; Ellis MS
JAMA Psychiatry; 2015 May; 72(5):424-30. PubMed ID: 25760692
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study.
Hartrick C; Van Hove I; Stegmann JU; Oh C; Upmalis D
Clin Ther; 2009 Feb; 31(2):260-71. PubMed ID: 19302899
[TBL] [Abstract][Full Text] [Related]
13. Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride.
Etropolski M; Kelly K; Okamoto A; Rauschkolb C
Adv Ther; 2011 May; 28(5):401-17. PubMed ID: 21494892
[TBL] [Abstract][Full Text] [Related]
14. Abuse and diversion of buprenorphine sublingual tablets and film.
Lavonas EJ; Severtson SG; Martinez EM; Bucher-Bartelson B; Le Lait MC; Green JL; Murrelle LE; Cicero TJ; Kurtz SP; Rosenblum A; Surratt HL; Dart RC
J Subst Abuse Treat; 2014 Jul; 47(1):27-34. PubMed ID: 24680219
[TBL] [Abstract][Full Text] [Related]
15. Abuse and Diversion of Immediate Release Opioid Analgesics as Compared to Extended Release Formulations in the United States.
Iwanicki JL; Severtson SG; McDaniel H; Rosenblum A; Fong C; Cicero TJ; Ellis MS; Kurtz SP; Buttram ME; Dart RC
PLoS One; 2016; 11(12):e0167499. PubMed ID: 27936038
[TBL] [Abstract][Full Text] [Related]
16. Bowel function after tapentadol and oxycodone immediate release (IR) treatment in patients with low back or osteoarthritis pain.
Kwong WJ; Hammond G; Upmalis D; Okamoto A; Yang M; Kavanagh S
Clin J Pain; 2013 Aug; 29(8):664-72. PubMed ID: 23835764
[TBL] [Abstract][Full Text] [Related]
17. Relationship between therapeutic use and abuse of opioid analgesics in rural, suburban, and urban locations in the United States.
Cicero TJ; Surratt H; Inciardi JA; Munoz A
Pharmacoepidemiol Drug Saf; 2007 Aug; 16(8):827-40. PubMed ID: 17636553
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the Abuse and Diversion of the Buprenorphine Transdermal Delivery System.
Wiegand TJ; Le Lait MC; Bartelson BB; Dart RC; Green JL
J Pain; 2016 Jun; 17(6):745-52. PubMed ID: 26996928
[TBL] [Abstract][Full Text] [Related]
19. Major increases in opioid analgesic abuse in the United States: concerns and strategies.
Compton WM; Volkow ND
Drug Alcohol Depend; 2006 Feb; 81(2):103-7. PubMed ID: 16023304
[TBL] [Abstract][Full Text] [Related]
20. Immediate-release tapentadol or oxycodone for treatment of acute postoperative pain after elective arthroscopic shoulder surgery: a randomized, phase IIIb study.
Vorsanger GJ; Klopfer AM; Xiang J; Benson CJ; Moskovitz BL; Rosenthal NR
J Opioid Manag; 2013; 9(4):281-90. PubMed ID: 24353022
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
